news aktuell GmbH

acousia Therapeutics GmbH: Hearing loss company Acousia Therapeutics to present data for ACOU085 at ARO 2022 MidWinter Meeting February 5–9

Share
Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen) and Synovo GmbH (Tübingen) – will be presenting data on the the company’s clinical stage lead candidate ACOU085 at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology to be held virtually on February 5–9, 2022.

(Tübingen, Germany): ACOU085 is a proprietary small molecule, otoprotective drug candidate. In December 2021, it was granted a CTA for initiation of first-in-human Phase 1b clinical trial by the German BfArM. The ACOU085 poster presentations at the 2022 ARO MidWinter Meeting will cover preclinical pharmacology, pharmacokinetic and local exposure data obtained using a a proprietary, sustained-release formulation for transtympanic administration.

Small-Molecule KCNQ4 Agonist Protects Against Outer Hair Cell Loss in the SAMP8 Mouse Model of Age-Related Hearing Loss (Peixoto Pinheiro et al.)

This proof-of-concept study uses the senescence-accelerated mouse prone 8 (SAMP8) model to demonstrate     the ability of repeated ACOU085 administrations to significantly reduce age-related ABR threshold shifts. This was supported by a histological demonstration of reduced OHC loss in this age-related hearing loss (ARHL) model using the novel KCNQ4 agonist ACOU085.

Translational Development of ACOU085 for the Prevention of Cisplatin-Induced Hearing Loss (CIHL) (Dyhrfjeld-Johnsen et al.)

This pharmacokinetic and local exposure study, compares the transtympanic administration of proprietary sustained-release formulations of ACOU085 in SAMP8 mice and guinea pigs with fixed drug load and administration volume relative to the species-specific inner ear volume. Significant inner ear exposure is achieved in both species, with a longer duration of exposure in the larger species receiving the largest absolute volume of the proprietary formulation.

About Acousia Therapeutics GmbH

Privately-held Acousia Therapeutics GmbH is based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia develops drugs for local and systemic applications.

Contacts

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Important step towards implementing the European Manufacturing-X vision - Catena-X meets Factory-X: GEC and Cofinity-X realize a showcase for interoperable data exchange26.1.2026 15:00:21 CET | Press release

German Edge Cloud (GEC) and Cofinity-X are implementing one of the first showcases for interoperable data exchange between Catena-X and Factory-X. The goal is to enable continuous, sovereign data flows across company and industry boundaries. This marks an important step toward seamlessly networked Manufacturing-X architectures in Europe.

Local playlists measurably improve hotel experience. HearDis! and Motel One present music study26.1.2026 09:30:00 CET | Press release

What people feel in a place is shaped not only by architecture, design, or service, but also by music. A new European pilot music study by HearDis! in collaboration with Motel One provides the first data-driven evidence of how local music influences the hotel experience. The results demonstrate clear positive effects on sense of place, guest satisfaction, and cultural curiosity.

McFIT “The Original” Launches International Franchising – One of Europe’s Most Recognized Fitness Brands Enters a New Era22.1.2026 12:00:00 CET | Press release

McFIT, a cornerstone of the European fitness landscape since 1997, is entering a new chapter in its corporate development: for the first time, the successful gym concept will be offered as an international franchise. This move paves the way for McFIT’s global franchise growth in previously untapped markets without company-owned locations.

How the CO2 price will affect heating costs in Europe22.1.2026 08:00:00 CET | Press release

The EU-wide uniform CO2 price for the building and transport sectors planned from 2028 will change the heating costs of 100 million households. A study by the Bertelsmann Stiftung shows that in many countries, including Germany, the additional burdens are likely to be limited. In Scandinavia, households could even see some relief. But in some Central and Eastern European regions, heating costs would go up noticeably. The study also shows that if the money from CO2 pricing is used the right way, it is enough to ease the burden households facing the greatest burden.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye